Mr. Ken d'Entremont reports

MEDEXUS SCHEDULES FIRST FISCAL QUARTER 2025 CONFERENCE CALL

Medexus Pharmaceuticals Inc. will host a conference call at 8 a.m. Eastern Time on Thursday, Aug. 8, 2024, to discuss Medexus's results for its first fiscal quarter ended June 30, 2024. Medexus expects to file its financial statements and management's discussion and analysis after markets close on Aug. 7, 2024.

To participate in the call, please dial the following numbers: 888-506-0062 (toll-free) for Canadian and U.S. callers, 1-973-528-0011 for international callers (access code: 570092).

A live webcast of the call will be available on the investors section of Medexus's corporate website or through the webcast host found on-line.

A replay of the call will be available approximately one hour following the end of the call through Thursday, Aug. 15, 2024. To access the replay, please dial the following numbers: 1-877-481-4010 for Canadian and U.S. callers, 1-919-882-2331 for international callers (conference ID: 50994).

A replay of the webcast will be available on the investors section of Medexus's corporate website until Friday, Aug. 8, 2025.

About Medexus Pharmaceuticals Inc.

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy and dermatology.

We seek Safe Harbor.